BLB-103

N/A

Report date: 2026/04/22 20:01:10

Base Information

Drug NameBLB-103
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Glypican-3DNA topoisomerase I inhibitors
TargetsGlypican-3DNA topoisomerase I
Therapy Area/IndicationsLung NeoplasmsLiver Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBaylink Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesBaylink Biosciences Inc
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsLiver Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A